Table 3.
Adults receiving inhaled and oral asthma medicines according to symptom severity stratified by country income group
|
High-income countries (n=2724) |
Upper-middle-income countries (n=2575) |
Lower-middle-income and low-income countries (n=1378) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Asymptomatic (n=1412) | Mild symptoms (n=677) | Severe symptoms (n=635) | Asymptomatic (n=1085) | Mild symptoms (n=551) | Severe symptoms (n=939) | Asymptomatic (n=618) | Mild symptoms (n=276) | Severe symptoms (n=484) | ||
| Inhaled medicine* | ||||||||||
| SABA (n=3030) | 314 (22·2%) | 391 (57·8%) | 471 (74·2%) | 262 (24·1%) | 366 (66·4%) | 727 (77·4%) | 112 (18·1%) | 109 (39·5%) | 278 (57·4%) | |
| LABA (n=718) | 39 (2·8%) | 53 (7·8%) | 80 (12·6%) | 47 (4·3%) | 128 (23·2%) | 230 (24·5%) | 49 (7·9%) | 23 (8·3%) | 69 (14·3%) | |
| Corticosteroids (n=1118) | 134 (9·5%) | 189 (27·9%) | 230 (36·2%) | 51 (4·7%) | 70 (12·7%) | 282 (30·0%) | 51 (8·3%) | 28 (10·1%) | 83 (17·1%) | |
| Corticosteroids and LABA† (n=1280) | 151 (10·7%) | 199 (29·4%) | 284 (44·7%) | 52 (4·8%) | 79 (14·3%) | 223 (23·7%) | 76 (12·3%) | 65 (23·6%) | 151 (31·2%) | |
| Any inhaled medicine (n=3646) | 350 (24·8%) | 439 (64·8%) | 534 (84·1%) | 333 (30·7%) | 409 (74·2%) | 823 (87·6%) | 178 (28·8%) | 185 (67·0%) | 395 (81·6%) | |
| Oral medicine* | ||||||||||
| LTRA (n=520) | 71 (5·0%) | 46 (6·8%) | 80 (12·6%) | 47 (4·3%) | 46 (8·3%) | 192 (20·4%) | 10 (1·6%) | 4 (1·4%) | 24 (5·0%) | |
| Corticosteroids (n=602) | 59 (4·2%) | 62 (9·2%) | 114 (18·0%) | 49 (4·5%) | 40 (7·3%) | 231 (24·6%) | 12 (1·9%) | 5 (1·8%) | 30 (6·2%) | |
| SABA (n=1004) | 101 (7·2%) | 127 (18·8%) | 185 (29·1%) | 83 (7·6%) | 64 (11·6%) | 316 (33·7%) | 29 (4·7%) | 29 (10·5%) | 70 (14·5%) | |
| Theophylline (n=307) | 47 (3·3%) | 40 (5·9%) | 68 (10·7%) | 18 (1·7%) | 27 (4·9%) | 78 (8·3%) | 1 (0·2%) | 5 (1·8%) | 23 (4·8%) | |
| Any oral medicine (n=2226) | 177 (12·5%) | 227 (33·5%) | 320 (50·4%) | 159 (14·7%) | 195 (35·4%) | 613 (65·3%) | 133 (21·5%) | 125 (45·3%) | 277 (57·2%) | |
| Asthma management plan (n=3168) | 461 (32·6%) | 270 (39·9%) | 321 (50·6%) | 521 (48·0%) | 276 (50·1%) | 651 (69·3%) | 217 (35·1%) | 128 (46·4%) | 323 (66·7%) | |
Data are n (%) where denominators are the total number in each symptom severity category per income group. Percentages with 95% CIs clustered by centre are provided in appendix 2 (p 7). SABA=short-acting β2 agonist. LABA=long-acting β2 agonist. LTRA=leukotriene receptor antagonist.
*
Drug therapy groups are not mutually exclusive and participants could be represented in more than one group.
†
Combined in the same inhaler; patients using LABA and corticosteroids in separate inhalers were included in the corresponding single-agent treatment groups.